Lantheus (NASDAQ:LNTH) Updates Q1 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.25 to $0.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.03. The company issued revenue guidance of $89 million to $91 million, compared to the consensus revenue estimate of $92.21 million.Lantheus also updated its FY 2020
Pre-Market guidance to 1.34-1.40 EPS.

A number of research firms recently issued reports on LNTH. BidaskClub upgraded Lantheus from a strong sell rating to a sell rating in a research report on Wednesday. ValuEngine upgraded Lantheus from a sell rating to a hold rating in a research note on Saturday, February 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $29.00.

NASDAQ:LNTH traded down $0.39 during mid-day trading on Wednesday, hitting $16.30. The stock had a trading volume of 699,539 shares, compared to its average volume of 405,727. The company has a current ratio of 2.59, a quick ratio of 2.08 and a debt-to-equity ratio of 1.84. The company has a 50 day simple moving average of $17.76 and a 200-day simple moving average of $20.46. The stock has a market capitalization of $650.96 million, a price-to-earnings ratio of 18.74 and a beta of 1.43. Lantheus has a 52 week low of $15.53 and a 52 week high of $29.80.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $0.34 EPS for the quarter, topping the consensus estimate of $0.30 by $0.04. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. The firm had revenue of $89.35 million during the quarter, compared to analysts’ expectations of $90.62 million. During the same quarter in the prior year, the firm earned $0.29 EPS. Lantheus’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts anticipate that Lantheus will post 1 earnings per share for the current year.

In related news, Director Sam R. Leno sold 11,508 shares of Lantheus stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $20.30, for a total transaction of $233,612.40. Following the sale, the director now directly owns 38,072 shares in the company, valued at $772,861.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Mary Anne Heino sold 19,260 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $20.85, for a total transaction of $401,571.00. Following the completion of the sale, the chief executive officer now directly owns 563,034 shares of the company’s stock, valued at approximately $11,739,258.90. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,017 shares of company stock worth $926,373. Corporate insiders own 2.60% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.